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Available online 14 February 2018Background. Linsitinib, an oral, dual inhibitor of insulin-like growth factor-1 receptor and insulin receptor, in
combination with weekly paclitaxel, may improve clinical outcomes compared with paclitaxel alone in patients
with refractory or platinum-resistant ovarian cancer.
Patients and methods. This open-label phase 1/2 clinical trial (NCT00889382) randomized patients with re-
fractory or platinum-resistant ovarian cancer (1:1:1) to receive either oral intermittent linsitinib (600 mg once
daily on Days 1–3 per week) combined with paclitaxel (80 mg/m2 on Days 1, 8, and 15; Arm A) or continuous
linsitinib (150mg twice daily) in combinationwith paclitaxel (Arm B), or paclitaxel alone (Arm C). Primary end-
point was progression-free survival (PFS); secondary endpoints included overall survival (OS), overall response
rate (ORR), disease control rate (DCR), and safety/tolerability.
Results.A total of 152womenwere randomized to treatment (n=51ArmA; n=51ArmB, n=50ArmC). In
combination with paclitaxel, neither intermittent linsitinib (median PFS 2.8 months; 95% conﬁdence interval
[CI]:2.5–4.4) nor continuous linsitinib (median PFS 4.2 months; 95% CI:2.8–5.1) improved PFS over weekly pac-
litaxel alone (median PFS 5.6 months; 95% CI:3.2–6.9). No improvement in ORR, DCR, or OS in either linsitinib
dosing schedule was observed compared with paclitaxel alone. Adverse event (AE) rates, including all-grade
and grade 3/4 treatment-related AEs, and treatment-related AEs leading to discontinuation, were higher
among patients receiving intermittent linsitinib compared with the other treatment arms.
Conclusion. Addition of intermittent or continuous linsitinib with paclitaxel did not improve outcomes in pa-
tients with platinum-resistant/refractory ovarian cancer compared with paclitaxel alone.er Centre
e Royal M
anerjee@
. This is a©2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)., University of Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada.
arsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.
rmh.nhs.uk (S. Banerjee).
n open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
276 A. Oza et al. / Gynecologic Oncology 149 (2018) 275–2821. BackgroundOvarian cancer is the second most common gynecologic cancer and
the most frequent cause of gynecologic cancer-related deaths in the
United States [1]. Although recent treatment advances have improved
survival, approximately 85% of patients with advanced ovarian
epithelial cancer will experience a recurrence and will eventually de-
velop resistance to chemotherapy [2]. The duration of response follow-
ing platinum therapy (platinum-free interval) as well as previous
platinum therapy response are key considerations when planning for
recurrent ovarian cancer management. Several chemotherapy agents,
such as pegylated liposomal doxorubicin and topotecan, are active in re-
lapsed platinum-resistant ovarian cancer (deﬁned as a relapse within
6 months of platinum treatment), most with a 10–30% response rate
for patients with a treatment-free interval of b6 months [3]. Weekly
paclitaxel is a treatment option in platinum-resistant disease with re-
sponse rates between 25% and 55% [4].
The combination of novel therapies targeting speciﬁc pathways
involved in ovarian cancer provides the potential to prolong
progression-free survival (PFS) in platinum-resistant ovarian cancer
[5,6]. One mechanism proposed for platinum and taxane resistance is
the presence of abnormalities in the insulin-like growth factor (IGF)-
signaling pathway, which play an important role in the growth and sur-
vival of multiple human cancers including ovarian cancer. Binding of
IGF1 or IGF2 to IGF1 receptors (IGF1Rs) activates the PI3K/AKTpathway,
leading to tumor survival andmetastasis [7,8]. Increased IGF1R, IGF1, or
IGF2 expression, as well as IGF1R activation, correlates with disease in-
cidence, progression, and prognosis in several tumor types [7,9]. Micro-
array studies in ovarian cancer have shown that upregulation of the IGF-
signaling pathway is associated with poor overall survival (OS) [10].
Preclinical studies have demonstrated that inhibition of IGF1R in
human tumor xenograft models may reduce tumor growth [11].
IGF1R-mediated pro-survival signaling is an important pathway in-
volved in acquired resistance to chemotherapeutic agents [12,13], in-
cluding resistance to platinum and paclitaxel in ovarian cancer [13].
Furthermore, inhibition of the IGF-signaling pathway by various IGF or
IGF1R blockers, such as metformin, picropodophyllin, or small hairpin
RNA, reversed cisplatin and/or paclitaxel resistance in cultured ovarian
cancer cells [14–17]. These observations provide a rationale for IGF1R
as a treatment target in ovarian cancer.
Linsitinib (OSI-906) is an orally active, dual IGF1R and insulin recep-
tor (IR) inhibitor, with anti-proliferative effects in tumor cell lines and
in vivo xenograft tumor models [18,19]. By inhibiting both IGF1R and
IR, linsitinib offers the potential for enhanced anticancer activity when
used in combination with chemotherapy. In a phase 1 study, linsitinib
monotherapy demonstrated clinical activity in patients with melanoma
and adrenocortical carcinoma [20,21]; however, this activity may be
limited. In a phase 3 study, linsitinib, administered as a single agent,
did not improve progression-free or overall survival comparedwith pla-
cebo in patients with locally advanced or metastatic adrenocortical car-
cinoma [22]. Linsitinib, however, has demonstrated antitumor activity
in combination with erlotinib in solid tumors [23], including non-
small cell lung cancer [24].
The rationale for combining paclitaxel with linsitinib was supported
by a body of preclinical evidence indicating the importance of IGF1R in-
hibition in ovarian cancer. The IGF-signaling pathway plays a critical
role in the development, maintenance, progression, survival, and che-
motherapeutic response associated with ovarian cancer [25]. IGF1 is
overexpressed in serous ovarian carcinoma [26], and IGF1R enhances
the proliferation and tumorigenicity of human ovarian cancer cells
[27]. Moreover, IGF1R signaling is associated with resistance in ovarian
carcinoma [17,28].
Continuous dosing of an oral drug with a relatively short half-life,
such as linsitinib, is a logical method to maintain therapeutic plasma
levels, but may also lead to increased toxicity. While preclinical studies
demonstrate the antitumor activity of intermittent linsitinib, it wasuncertain whether tumor growth inhibition with intermittent dosing
would be maintained to the same extent as with continuous dosing.
Thus, both intermittent and continuous dosing schedules of linsitinib
were used in combination with weekly paclitaxel to identify the opti-
mum dosing regimen that would achieve efﬁcacywhile avoiding signif-
icant toxicity.
Here, we present the results of the phase 2 portion of a multicenter,
randomized, open-label phase 1/2 study, which evaluated intermittent
or continuous linsitinib plus continuous weekly paclitaxel versus pacli-
taxel alone in patients with recurrent/relapsed epithelial ovarian cancer
(NCT00889382). The phase 1 portion of the study established the phase
2 recommended doses (combined with weekly paclitaxel) of 600 mg
once daily for intermittent linsitinib, and 150mg twice daily for contin-
uous linsitinib; it also showed preliminary efﬁcacy, with six partial re-
sponses and 25 patients with stable disease from a cohort of 58
patients with ovarian cancer [29].
2. Methods
2.1. Study oversight
The study was conducted in accordance with the International Con-
ference on Harmonisation (ICH) Good Clinical Practice (GCP) with the
ethical principles of Helsinki, and approved by the independent ethics
committee or institutional review board for each study site. All patients
provided written informed consent.
2.2. Patients
Patients with histologically or cytologically conﬁrmed ovarian epi-
thelial carcinoma, fallopian cancer, or peritoneal cancer were enrolled.
Patients had received prior therapy with platinum plus a taxane, with
the taxane administered on a 3-week schedule. A maximum of two
prior chemotherapy regimens was permitted. Eligible patients were re-
fractory (progressive disease [PD] during chemotherapy) or resistant
(PD within 6 months of completing chemotherapy) to their last
platinum-containing chemotherapy regimen. Patients had radiologi-
cally conﬁrmed PD by RECIST (v1.1) [3]. Exclusion criteria included
prior therapywithweekly paclitaxel, subjectswith diabetesmellitus re-
quiring medications, those with brain metastases, and those with an
ECOG performance status ≥2 (see supplement for full patient criteria).
2.3. Study design
This open-label,multicenter, international study evaluated linsitinib,
administered either intermittently (Arm A) or continuously (Arm B),
combined with weekly paclitaxel, compared with weekly paclitaxel
alone (Arm C); patients were randomized 1:1:1 to each treatment
arm. Intermittent linsitinib was administered orally, once daily, at a
dose of 600mg on Days 1–3 of eachweek of a 21-day treatment period;
continuous linsitinib was administered orally, twice daily, at a dose of
150 mg. All patients received weekly intravenous paclitaxel at
80 mg/m2 on Days 1, 8, and 15 of each 21-day treatment period.
Dose modiﬁcations were allowed at the discretion of the investiga-
tor. Re-escalation of dose was not permitted. If a study drug was
discontinued, the patient could remain on the other assigned drug. Pa-
tients who experienced disease progression on single-agent paclitaxel
(Arm C) were allowed to receive a continuous daily dosing of linsitinib.
2.4. Assessments
The primary endpoint was PFS based on RECIST version 1.1. Second-
ary efﬁcacy endpoints included OS, calculated from randomization to
death from any cause; CA-125 response; overall response rate (ORR),
deﬁned as the proportion of patients with complete response (CR) or
partial response (PR) according to RECIST v1.1; and disease control
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endpoints were safety proﬁle, pharmacokinetic (PK) parameters, and
exploratory biomarker analysis, which included evaluation of Kirsten
rat sarcoma viral oncogene homologue (KRAS), phosphatidylinositol-
4,5-bisphosphate 3-kinase, catalytic subunit alpha (PI3KCA), and phos-
phatase and tensin homologue (PTEN) mutations in available archival
tissue samples. IGF1 plasma concentration assessments were also
performed.
All patients were included in the efﬁcacy evaluation (intent-to-treat
population). All patients who received at least one dose of treatment
were included in safety evaluations, which were performed using
National Cancer Institute Common Terminology Criteria for Adverse
Events (NCI-CTCAE) v4.02.
2.5. Statistical analysis
Kaplan–Meier survival plots were used to determine the primary
endpoint of PFS and the secondary endpoint of OS in each treatment
arm. Hazard ratios (HRs) of the treatment effects, along with the 95%
conﬁdence intervals (CIs), were calculated using a Cox proportional
hazard model. Patients were stratiﬁed by the number of prior chemo-
therapy regimens (one vs two) and the outcome of the most recent
platinum-containing chemotherapy regimen (refractory vs resistant).
Variables for response rates, CA-125, DCR, and ORR were analyzed
using Fisher's exact test. The exact 95% CI (Clopper–Pearson)was calcu-
lated for each treatment arm. The CA-125 response rate was summa-
rized based on the CA-125 evaluable population.
3. Results
3.1. Patient demographics
A total of 152 patients were randomized from 46 centers between
2009 and 2014: 51 patients to Arm A, 51 to Arm B, and 50 to Arm C;
studyﬂowand patient disposition are depicted in Fig. 1. Baseline patient
characteristics were balanced among the three arms (Table 1). MedianRandom
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Fig. 1. Study ﬂow chart of patient disposition. Footer: The chart displays the assignment of patie
SAS, safety analysis set.age was 58 years (range 18–77 years). A total of 96 patients (63.2%)
had serous histology and 17 (11.2%) had clear cell carcinoma. Of the
152 patients, 80 (52.6%) received one prior line of chemotherapy and
72 (47.4%) received two prior lines. A small number of patients had
prior radiation therapy (3.9%) or prior hormonal therapy and immuno-
therapy (5.9%).
3.2. Drug exposure
Themedianduration of exposure to linsitinibwas 62.5 days inArmA
and 103.0 days in Arm B. Median duration of exposure to paclitaxel was
64.0 days in Arm A, 106.0 days in Arm B, and 119 days in Arm C. Study
drug treatmentwas discontinued inmost patients (98% in ArmA, 90% in
Arm B, and 92% in Arm C; Fig. 1). Themost common primary reason for
drug discontinuation was disease progression (78% in Arm A, 70% in
Arm B, and 61% in Arm C). Linsitinib dose reductions were similar in
Arms A and B (40% and 49%, respectively), while 60% of patients had a
dose reduction of paclitaxel in Arm A, compared with 43% in Arm B
and 35% in Arm C.
3.3. Efﬁcacy
The trial did notmeet its primary endpoint. Therewere no statistically
signiﬁcant differences in median PFS between the three treatment arms
(2.8 months for Arm A, 4.2 months for Arm B, and 5.6 months for Arm
C; HRs for Arm A and Arm B vs Arm C was 1.3, P= 0.268; and 1.2, P=
0.452, respectively; Table 2). In addition, there was no difference in PFS
according to the number of prior chemotherapy regimens, the outcome
of most recent platinum-containing chemotherapy regimen (refractory
or resistant), or according to age group (≤65 years or N65 years).
There was no difference in median OS between the three treatment
arms, with the median OS for Arm A at 16.0 months (95% CI, 10.1–NR),
ArmB at 10.4months (95% CI, 7.9–14.7), andArmC at 18.0months (95%
CI, 8.1–NR). In addition, an OS analysis excluding the 10 patients who
crossed over to linsitinib after discontinuing paclitaxel alone showed
no difference in OS (HR = 0.961, 95% CI, 0.375–2.463; P= 0.934).ized
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Table 1
Baseline patient characteristics.
Intermittent linsitinib/paclitaxel
(Arm A; n = 51)
Continuous linsitinib/paclitaxel
(Arm B; n = 51)
Paclitaxel
(Arm C; n = 50)
Total
(n = 152)
Age, median (range) 58.0 (18.0–74.0) 59.0 (37.0–77.0) 56.0 (37.0–76.0) 58.0 (18.0–77.0)
% ≤65 years 76.5 88.2 82.0 82.2
% N65 years 23.5 11.8 18.0 17.8
Race, n (%)
White 49 (96.1) 47 (92.2) 45 (90.0) 141 (92.8)
Asian 1 (2.0) 1 (2.0) 4 (8.0) 6 (3.9)
Other 1 (2.0) 3 (5.9) 1 (2.0) 5 (3.3)
ECOG performance score, n (%)
0 31 (60.8) 23 (45.1) 31 (62.0) 85 (55.9)
1 19 (37.3) 28 (54.9) 19 (38.0) 66 (43.4)
2 1 (2.0) 0 0 1 (0.7)
Tumor type, n (%)
Ovarian – papillary serous 35 (68.6) 27 (52.9) 34 (68.0) 96 (63.2)
Ovarian – endometrioid 0 5 (9.8) 3 (6.0) 8 (5.3)
Ovarian – clear cell 5 (9.8) 6 (11.8) 6 (12.0) 17 (11.2)
Ovarian –mucinous 0 0 2 (4.0) 2 (1.3)
Ovarian – other 8 (15.7) 6 (11.8) 2 (4.0) 16 (10.5)
Fallopian 0 2 (3.9) 2 (4.0) 4 (2.6)
Peritoneal 3 (5.9) 4 (7.8) 1 (2.0) 8 (5.3)
Missing 0 1 (2.0) 0 1 (0.7)
Prior radiation therapy, n (%) 1 (2.0) 2 (3.9) 3 (6.0) 6 (3.9)
Prior disease-related surgery, n (%) 51 (100) 50 (98.0) 50 (100) 151 (99.3)
Prior hormonal therapy and immunotherapy, n (%) 4 (7.8) 4 (7.8) 1 (2.0) 9 (5.9)
Prior chemotherapy, n (%) 51 (100) 50 (98.0)a 50 (100) 151 (99.3)
1 regimen 24 (47.1) 29 (56.9) 27 (54.0) 80 (52.6)
2 regimens 27 (52.9) 22 (43.1) 23 (46.0) 72 (47.4)
Platinum-free interval status, n(%)
Refractory 15 (29.4) 7 (13.7) 14 (28.0) 36 (23.70)
Resistant 36 (70.6) 44 (86.3) 36 (72.0) 116 (76.30)
Best response to prior chemotherapy, n (%)
Complete response 19 (37.3) 13 (25.5) 18 (36.0) 50 (32.9)
Partial response 17 (9.8) 18 (35.3) 12 (24.0) 47 (30.9)
Stable disease 5 (9.8) 8 (15.7) 9 (18.0) 22 (14.5)
Progressive disease 7 (13.7) 7 (13.7) 10 (20.0) 24 (15.8)
Not evaluable 1 (2.0) 2 (3.9) 0 (00029 3 (2.0)
Unknown 2 (3.9) 3 (5.9) 1 (2.0) 6 (3.9)
ECOG, Eastern Cooperative Oncology Group.
a One patient with missing data.
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in Arm C. No CRs were reported for patients in Arms A or B, while there
were three reported for patients in Arm C (6.0%; Table 2). DCR was
58.8% in Arm A, 72.6% in Arm B, and 74.0% in Arm C, and the CA-125 re-
sponse rate was 35.7% in Arm A, 50.0% in Arm B, and 62.2% in Arm C
(Table 2).Table 2
Summary of efﬁcacy of intermittent linsitinib + paclitaxel (Arm A); continuous linsitinib + pa
Intermittent linsitinib/paclita
(Arm A; n = 51)
Progression-free survival
Number of events, n (%) 39 (76.5)
Median, months (95% CI) 2.8 (2.5, 4.4)
HR versus paclitaxel alone; P-value (95% CI) 1.3; 0.268 (0.81–2.09)
Overall survival
Number of events, n (%) 20 (39.2)
Median, months (95% CI) 16.0 (10.1–NR)
HR versus paclitaxel alone; P-value (95% CI) 0.79; 0.451 (0.44–1.45)
Best response, n (%)
Complete response 0 (0)
Partial response 9 (17.7)
Stable disease 21 (41.2)
Progressive disease 12 (23.5)
Not evaluated 9 (17.7)
Disease control ratea, n (%) 95% CI 30 (58.8) (44.2–72.4)
Objective response rateb, n (%) 95% CI 9 (17.7) (8.4–30.9)
CA-125 response ratec, n (%) 95% CI 15 (35.7) (21.6–52.0)
CI, conﬁdence interval; HR, hazard ratio; NA, not applicable; NR, not reached.
a Disease control rate = complete response + partial response + stable disease.
b Overall response rate = complete response + partial response.
c CA-125 responders were those patients who had two consecutive post-baseline visits (at l3.4. Pharmacokinetics and pharmacodynamics
On both Days 1 and 22, intermittent dosing of 600 mg linsitinib
resulted in higher AUC0-∞ and Cmax than the continuous dosing
schedule, and median values of the PK parameters were generally
consistent between Day 1 and Day 22 for both Arms A and Bclitaxel (Arm B); paclitaxel only (Arm C).
xel Continuous linsitinib/paclitaxel
(Arm B; n = 51)
Paclitaxel
(Arm C; n = 50)
38 (74.5) 33 (66.0)
4.2 (2.8, 5.1) 5.6 (3.2–6.9)
1.2; 0.452 (0.75–1.91) NA
29 (56.9) 23 (46.0)
10.4 (7.9–14.7) 18.0 (8.1–NR)
1.4; 0.208 (0.82–2.46) NA
0 (0) 3 (6.0)
11 (21.6) 14 (28.0)
26 (51.0) 20 (40.0)
9 (17.7) 10 (20.0)
5 (9.8) 3 (6.0)
37 (72.6) (58.3–84.1) 37 (74.0) (59.7–85.4)
11 (21.6) (11.3–35.3) 17 (34.0) (21.2–48.8)
21 (50.0) (34.2–65.8) 23 (62.2) (44.8–77.5)
east 28 days apart) with a 50% decrease from baseline.
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concentrations at approximately 1 h (end of infusion). Pharmacoki-
netic parameters were generally consistent for paclitaxel between
Day 1 and Day 22 (Table 3). Co-administration of linsitinib in Arms
A and B did not alter the pharmacokinetics of paclitaxel, compared
with Arm C.
In Arms A and C, pre-dose median plasma concentrations of IGF1
remained similar from Day 1 through Day 43 (Table 4). Plasma IGF1
levels were higher by Day 8 in patients receiving continuous
linsitinib dosing (Arm B); these levels remained elevated and nearly
constant from Days 15–43. The increases in plasma levels of IGF1
were not associated with improved efﬁcacy compared with pacli-
taxel alone.
KRAS, PIK3CA, and PTEN mutations were evaluated in patients for
whom samples were available, which was approximately 50% of pa-
tients in each arm. Mutations were present in ≤5 patients in each treat-
ment arm: KRAS, Arm A (n=1), Arm B (n=1); PI3KCA, Arm A (n=4),
Arm B (n= 2); PTEN, Arm A (n= 4), Arm B (n= 5); therefore, further
analysis was not performed.3.5. Safety
Treatment-emergent AEs were reported in almost all patients, in-
cluding grade 3/4 AEs in 72.0% of patients in Arm A, 40.8% in Arm B,
and 20.8% in Arm C. Serious AEs were reported in 36.0% of patients in
Arm A, 36.7% in Arm B, and 34.7% in Arm C. All-grade treatment-
relatedAEswere reported in a total of 94.6% of patients,with thehighest
proportion of grade 3/4 treatment-related AEs reported in ArmA (52.0%
in Arm A, 32.7% in Arm B, and 28.6% in Arm C; Table 5). The most com-
mon treatment-related AEs were fatigue (42% in ArmA, 44.9% in Arm B,
and 51.0% in Arm C) and nausea (56.0%, 32.7%, and 42.9%, respectively).
Overall, thereweremore patients in ArmAwhodiscontinued treatment
due to a primary cause of a drug-related AE (30.0% of patients in Arm A,
14.3% in Arm B, and 16.3% in Arm C). In Arm A, 60% of patients had no
linsitinib reduction, 40% had no paclitaxel reduction. In Arm B, 51%
and 57.1% of patients had no reduction of linsitinib and paclitaxel,Table 3
(A) Pharmacokinetics of linsitinib (Arms A and B) and (B) pharmacokinetics of paclitaxel (Arm
A
Intermittent linsitinib/paclitaxel (Arm A) – Linsitinib data
Day 1 Day 22
Cmax (ng/mL)
Evaluable, n 48 42
Median (Range) 4515.0 (903.0–14,500.0) 3670.0 (0.0–703
tmax (h)
Evaluable, n 48 39
Median (Range) 2.0 (1.0–8.1) 4.0 (1.0–8.0)
AUC0-∞ (h*ng/mL)
Evaluable, n 48 42
Median (Range) 22,667.9 (3330.3–79,718.2) 18,622.6 (0.0–38
B
Paclitaxel (Arm C)
Day 1
Cmax (ng/mL)
Evaluable, n 47
Median (Range) 2500.0 (159.0–207,
tmax (h)
Evaluable, n 47
Median (Range) 1.0 (0.0–8.0)
AUC0-∞ (h*ng/mL)
Evaluable, n 41
Median (Range) 3578.7 (318.0–10,2respectively, compared with 65.3% of patients in Arm C who did not
have paclitaxel dose reduction.
Adverse events of special interest to linsitinib include hypergly-
cemia, hypoglycemia, and prolonged QTc interval. Hyperglycemic
events considered to be treatment related were observed in 2.0% of
patients in Arm A, 10.2% in Arm B, and 2.0% in Arm C. Grades 3/4 hy-
perglycemic events were reported in 2.0% of patients in Arm A, 6.1%
of patients in Arm B, and no patients in Arm C. One hyperglycemic
event (in Arm A) was deemed serious; none of the events warranted
discontinuation from the study. Cardiac AEs included peripheral
edema and prolonged QT intervals by electrocardiography. Two
patients in Arm B reported serious cardiac events. One patient expe-
rienced cardiac arrest on Day 16 of the study, which was not consid-
ered to be related to study drug (by the investigator). The other
patient experienced a grade 2 myocardial infarction, which was con-
sidered by the investigator to be related to paclitaxel; the dose was
interrupted, but not modiﬁed, in response to this AE. All-grade QT
prolongation was observed in a higher proportion of patients receiv-
ing the 600 mg intermittent schedule (32.0% in Arm A, 4.1% in Arm B,
and 0% in Arm C).
There were 13 deaths due to AEs; of which 11 occurred while the
patient was on treatment or within 30 days of the last dose, and the
remaining two occurred during follow-up. In Arm B, one patient
progressed to grade 5 pulmonary embolism, possibly related to
linsitinib and paclitaxel, and grade 5 pneumonitis, possibly related
to linsitinib and probably related to paclitaxel. The other causes of
death were: in Arm A, respiratory arrest (n = 1); in Arm B, cancer
recurrence/progression (n = 4), sepsis (n = 1), and ileus (n = 1);
and, in Arm C, intestinal obstruction (n = 2) and cardiovascular in-
sufﬁciency (n = 1). Two additional deaths due to intestinal obstruc-
tion, one in Arm B and one in Arm C, occurred N30 days after the last
dose.
4. Discussion
In this randomized phase 2 study of weekly paclitaxel combined
with either intermittent or continuous dosing of linsitinib, neitherC).
Continuous linsitinib/paclitaxel (Arm B) – Linsitinib data
Day 1 Day 22
48 35
0.0) 1475.0 (220.0–4530.0) 2110.0 (19.3–5200.0)
48 35
1.1 (0.0–8.0) 2.0 (0.0–8.0)
48 35
,225.3) 4630.2 (906.7–14,059.1) 9564.7 (22.6–26,471.4)
Day 22
45
000.0) 2350.0 (182.0–20,000.0)
45
1.1 (0.2–4.0)
38
76.6) 3214.2 (610.0–16,094.5)
Table 4
Pre-dose plasma concentrations of insulin-like growth factor-1 (IGF1) (full analysis set).
Intermittent linsitinib/paclitaxel (Arm
A)
Continuous linsitinib/paclitaxel (Arm
B)
Paclitaxel (Arm C)
n Median (range), ng/mL n Median (range), ng/mL n Median (range), ng/mL
Day 1 46 44.03 (11.97–81.11) 45 35.10 (4.91–111.71) 44 39.21 (2.67–111.84)
Day 8 46 47.90 (13.83–118.48) 42 52.83 (3.27–128.08) 43 40.75 (4.67–119.41)
Day 15 43 50.22 (10.06–90.24) 40 72.16 (16.92–170.63) 44 40.33 (7.07–114.08)
Day 22 43 48.20 (10.18–91.40) 43 61.87 (17.47–184.80) 44 45.36 (10.49–97.09)
Day 43 29 49.33 (12.04–101.54) 34 71.38 (21.54–157.99) 33 44.96 (5.76–114.33)
280 A. Oza et al. / Gynecologic Oncology 149 (2018) 275–282dosing regimen led to improvement in PFS or OS over paclitaxel alone in
patients with platinum-resistant or -refractory epithelial ovarian can-
cer. Weekly paclitaxel is a common standard treatment option for
women with platinum-resistant/refractory ovarian cancer. The median
PFS is approximately 4.0–7.0 months, demonstrating an urgent need
to develop agents that can delay taxane resistance [30,31]. The addition
of antiangiogenic agents, such as bevacizumab (a VEGFA antibody),
pazopanib (a multi-targeted tyrosine kinase inhibitor of VEGF recep-
tors), and trebananib (an anti-angiopoietin), toweekly paclitaxel signif-
icantly improves PFS [6,32,33]. Bevacizumab is currently approved in
combination with paclitaxel in platinum-resistant ovarian cancer
[6,34,35]. However, antiangiogenic agents are not suitable for all pa-
tients with platinum-resistant/refractory ovarian cancer. Therefore,
the development of other novel drug–chemotherapy combinations is
needed. In light of the evidence suggesting that the IGF1R-signaling
pathway reversibly confers resistance to taxanes and platinum in pa-
tients with ovarian cancer, inhibiting this pathway appears to be a
promising target to develop drugs that could restore sensitivity to che-
motherapeutic agents [14,16,17]. This background prompted us to in-
vestigate the therapeutic effects of combining linsitinib, a novel oral
IR/IGF1R inhibitor, with paclitaxel. Several monoclonal antibodies that
inhibit this pathway are also being studied, including ganitumab
(AMG 479), a fully human monoclonal antibody against IGF1R, that
has shown synergistic and additive effects with carboplatin or
paclitaxel in ovarian cancer cell lines [36]; and dalotuzumab, aTable 5
All-grade treatment-related AEs ≥10% patients in either treatment and grade 3/4 treatment-re
Adverse event, n (%) Intermittent linsitinib/paclitaxel
(Arm A; n = 50)
Continuous
(Arm B; n =
All-grade Grade 3/4 All-grade
Any treatment-related AE 50 (100) 26 (52.0) 43 (87.8)
Fatigue 21 (42.0) 2 (4.0) 22 (44.9)
Nausea 28 (56.0) 0 16 (32.7)
Alopecia 10 (20.0) 0 15 (30.6)
Anemia 9 (18.0) 3 (6.0) 10 (20.4)
Diarrhea 17 (34.0) 1 (2.0) 9 (18.4)
Peripheral neuropathy 7 (14.0) 0 7 (14.3)
Vomiting 14 (28.0) 2 (4.0) 5 (10.2)
Constipation 6 (12.0) 0 10 (20.4)
Nail disorder 5 (10.0) 0 5 (10.2)
Neutropenia 12 (24.0) 10 (20.0) 3 (6.1)
Asthenia 10 (20.0) 1 (2.0) 4 (8.2)
Drug eruption 9 (18.0) 0 4 (8.2)
Prolonged QT electrocardiogram 16 (32.0) 2 (4.0) 2 (4.1)
Paresthesia 6 (12.0) 1 (2.0) 7 (14.3)
Anorexia 3 (6.0) 0 9 (18.4)
Dysgeusia 1 (2.0) 0 5 (10.2)
Peripheral sensory neuropathy 6 (12.0) 0 2 (4.1)
Stomatitis 6 (12.0) 0 3 (6.1)
Arthralgia 2 (4.0) 0 4 (8.2)
Mucosal inﬂammation 3 (6.0) 0 2 (4.1)
Abdominal pain 1 (2.0) 1 (2.0) 1 (2.0)
Dyspepsia 5 (10.0) 0 0
Hyperglycemia 1 (2.0) 1 (2.0) 5 (10.0)
Nail discoloration 0 0 2 (4.1)
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase.humanized anti-IGF1R antibody that in combination therapy in pa-
tients with high IGF1 expression ovarian cancer resulted in two pa-
tients achieving stable disease who remained on treatment for at
least 4 months [37].
Our results showed PFSwas longer in theweekly paclitaxel only arm
(Arm C), compared with both linsitinib combination arms (Arms A and
B). Grades 3 and 4 AEs were more frequent in intermittent linsitinib
dosing than continuous dosing; this may be due patients being exposed
to higher peak drug concentrations arising from higher single doses in
intermittent dosing. The decreased tolerability to the intermittent dos-
ing schedule leading to drug discontinuations and dose reductions
may partly explain the shorter PFS observed for this arm compared
with the continuous dosing arm and to paclitaxel alone arm. Patients re-
ceiving the intermittent schedule of linsitinib with paclitaxel had a de-
creased median exposure to paclitaxel treatment compared with the
other arms, and it is possible that these patients had a shorter PFS due
to a lower exposure to paclitaxel. Importantly, coadministration of
linsitinib with either intermittent or continuous dosing did not alter
the concentration proﬁle of paclitaxel comparedwith patients receiving
paclitaxel alone, suggesting an absence of inhibition of paclitaxel by
linsitinib.
ThemedianPFS and response rate in theweekly paclitaxel alone arm
of this randomized trial was consistent with previous recent studies in
this patient population [34,38]. Disappointingly, the SaPPrOC trial, a
randomized, placebo-controlled trial of weekly paclitaxel and a Src/lated AEs.
linsitinib/paclitaxel
49)
Paclitaxel
(Arm C; n = 49)
Total (n = 148)
Grade 3/4 All-grade Grade 3/4 All-grade Grade 3/4
16 (32.7) 47 (95.9) 14 (28.6) 140 (94.6) 56 (37.9)
1 (2.0) 25 (51.0) 1 (2.0) 68 (45.9) 4 (2.7)
1 (2.0) 21 (42.9) 0 65 (43.9) 1 (0.7)
0 19 (38.8) 0 44 (29.7) 0
0 17 (34.7) 3 (6.1) 36 (24.3) 6 (4.1)
1 (2.0) 10 (20.4) 0 36 (24.3) 2 (1.4)
1 (2.0) 17 (34.7) 2 (4.1) 31 (20.9) 3 (2.0)
2 (4.1) 9 (18.4) 0 28 (18.9) 4 (2.7)
1 (2.0) 10 (20.4) 0 26 (17.6) 1 (0.7)
1 (2.0) 11 (22.4) 1 (2.0) 21 (14.2) 2 (1.4)
3 (6.1) 4 (8.2) 3 (6.1) 19 (12.8) 16 (10.8)
0 4 (8.2) 1 (2.0) 18 (12.2) 2 (1.4)
0 5 (10.2) 0 18 (12.2) 0
0 0 0 18 (12.2) 2 (1.4)
1 (2.0) 4 (8.2) 0 17 (11.5) 2 (1.4)
0 3 (6.1) 0 15 (10.1) 0
0 8 (16.3) 0 14 (9.5) 0
0 5 (10.2) 0 11 (7.4) 1 (0/7)
0 3 (6.1) 0 12 (8.1) 0
0 5 (10.2) 0 11 (7.4) 0
0 5 (10.2) 1 (2.0) 10 (6.8) 1 (0.7)
0 5 (10.2) 0 7 (4.7) 1 (0.7)
0 2 (4.1) 0 7 (4.7) 0
3 (6.1) 1 (2.0) 0 7 (4.7) 4 (2.7)
0 5 (10.2) 0 7 (4.7) 0
281A. Oza et al. / Gynecologic Oncology 149 (2018) 275–282Bcr-Abl tyrosine kinase inhibitor saracatinib (AZD0530) in platinum-
resistant ovarian cancer, which was also supported by preclinical
work, similarly did not show an improvement in activity of weekly pac-
litaxel [38]. The results of these two negative randomized trials of
weekly paclitaxel in combination with novel (non-antiangiogenic)
agents indicate the importance of gaining a better understanding of
the signaling pathways involved in taxane resistance, and the identiﬁca-
tion of subgroups that may derive beneﬁt. A limitation of this linsitinib–
paclitaxel trial is that the protocol did notmandate tissue sample collec-
tion for biomarker analyses, and hence, the numbers of tissue samples
collected were too low for meaningful interpretation. Analyses of circu-
lating biomarkers, such as IGF2 and IGFBP, may have provided further
information; however, IGF1 levels were measured and were not associ-
ated with efﬁcacy.
Despite the negative results of this ﬁrst randomized trial targeting
IGF1Rwith chemotherapy in ovarian cancer, there is a rationale for fur-
ther investigation of IGF signaling in this disease, including targeting
other molecules in the pathway and different combinations. Preclinical
studies suggest that targeting IGF2 may be a preferable strategy com-
pared with targeting IGF1R alone in taxane-resistant ovarian cancer
[14]. In addition, in BRCA1-deﬁcient ovarian cancer models, cells with
impaired homologous recombination demonstrate over-activation of
the IGF1R pathway and aremore sensitive to IGF1R inhibition compared
with homologous recombination-proﬁcient cells. Furthermore, IGF-IR
inhibition appeared to sensitize cells to poly-ADP ribose polymerase in-
hibitors, [39] suggesting that targeting of both IGF-1R and PARP could
be an effective combination strategy increasing the population of pa-
tient who may beneﬁt from these approaches.
In conclusion, this is the ﬁrst randomized trial of an IGF1R inhibitor
in ovarian cancer. This study investigated two dosing regimens of
linsitinib in combination with weekly paclitaxel in patients with
platinum-resistant/refractory ovarian cancer and found no beneﬁt of ei-
ther an intermittent or continuous linsitinib dosing schedule, compared
with weekly paclitaxel alone, in terms of PFS, ORR, or OS. Further work
on the signiﬁcance of the IGF-signaling pathway in platinum-resistant
ovarian cancer is needed.
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